Rituximab and intense chemotherapy in a patient with defective cell mediated immunity due to cartilage-hair hypoplasia and Burkitt lymphoma.

MLA

Speckhart, Beth A., et al. “Rituximab and Intense Chemotherapy in a Patient with Defective Cell Mediated Immunity Due to Cartilage-Hair Hypoplasia and Burkitt Lymphoma.” Pediatric Blood & Cancer, vol. 67, no. 7, July 2020, p. e28259. EBSCOhost, https://doi.org/10.1002/pbc.28259.

APA

Speckhart, B. A., Bugaieski, E., Antony, R., & Fernandez, K. S. (2020). Rituximab and intense chemotherapy in a patient with defective cell mediated immunity due to cartilage-hair hypoplasia and Burkitt lymphoma. Pediatric Blood & Cancer, 67(7), e28259. https://doi.org/10.1002/pbc.28259

Chicago

Speckhart, Beth A, Eric Bugaieski, Reuben Antony, and Karen S Fernandez. 2020. “Rituximab and Intense Chemotherapy in a Patient with Defective Cell Mediated Immunity Due to Cartilage-Hair Hypoplasia and Burkitt Lymphoma.” Pediatric Blood & Cancer 67 (7): e28259. doi:10.1002/pbc.28259.